“Every day this bribery scandal becomes more credible,”

New Post Public Reply Private Reply Replies (1) Message Board
dw Bhawks #108226
198
“Every day this bribery scandal becomes more credible,” House Oversight Committee Chairman James Comer (R-Ky.) told Fox News host Sean Hannity on Monday night. The bribery scandal to which Comer is referring is the one he injected into the political conversation nearly three months ago — one alleging that President Biden took a substantial bribe from an executive with the Ukrainian energy company Burisma.

Despite Comer’s claim, though, the allegation is not becoming more credible every day. In fact, it is no more credible now than it was in early May, when Comer and Sen. Chuck Grassley (R-Iowa) first introduced it. But Hannity and Comer have a vested interest in presenting the allegation as credible and a vested interest in suggesting that closed-door testimony from one of Joe Biden’s son Hunter’s former business partners, Devon Archer, added to that credibility.

At this point, it does not. And to see why it does not, consider the central argument made by Comer, Hannity and House Judiciary Chairman Jim Jordan (R-Ohio) on Monday night — an argument that is easily debunked right at the start.

The argument centers on Hunter Biden’s and Archer’s positions on the board of Burisma during the time that Joe Biden was serving as vice president.


There is no real dispute — and there has never been any real dispute — that Hunter Biden’s role was a function of his presenting himself as a conduit to his father. Instead, the debate is over the extent to which that presentation was accurate. To date, there has been no evidence tying Joe Biden to Hunter Biden’s work in any concrete way, with the White House insisting that the president wasn’t involved in Hunter Biden’s business.

The bombshell that was promised from Archer’s testimony was that Hunter Biden would sporadically call his dad while in the presence of business partners, again to reinforce his purported access. But this comports with the idea that Hunter Biden was selling this perception. The lack of evidence looping President Biden into any business decisions or profit, despite years of searching, undercuts the insinuation that Biden was corrupted by these calls. Comer and Jordan are often left simply insisting that Biden’s past denials of involvement are eroded by his having taken his son’s calls.

On Hannity’s show, Comer tried to build the case that, as vice president, Biden’s role was more significant. He claimed that Archer “said that Hunter Biden was under immense pressure while they both served on the Burisma board to call Washington, D.C., immediately and try to get [Ukrainian prosecutor general Viktor] Shokin fired. And, according to Jordan’s account, five days later, Joe Biden traveled to Ukraine.” Speaking to Ukraine’s legislative body on Dec. 9, 2015, he demanded that Shokin be ousted.

Hannity repeated the timeline for his viewers: Hunter Biden, Archer and the head of Burisma, Mykola Zlochevsky, met with the board of the company in Dubai. They called Washington and, “then immediately thereafter,” Biden headed for Ukraine. Comer agreed, saying that “they were pressuring Hunter to immediately get on the phone with his father and get this stopped.”

Fine. Except that Joe Biden’s trip to Ukraine was announced in mid-November. And except that, in mid-September, the American ambassador to Ukraine elevated concerns about Shokin’s reliability in the fight against corruption — the reason Joe Biden offered for demanding that Shokin be fired.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Kinetic Seas Incorporated Secures First Customer Success

Updated Category News Views 56

Kinetic Seas Incorporated Secures First Customer and Financial Growth Kinetic Seas Incorporated (OTC: ECGR) is excited to announce the signing of its first customer, along with impressive revenue results for the second quarter. This milestone marks a significant step forward as the company pursues its goals in the artificial intelligence sector. Second Quarter Revenue...

Continue Reading
Webinar Guide for Veterans to Maximize Benefits Offered by CCK Law

Updated Category News Views 134

Helping Veterans Discover VA Benefits with a Free Webinar Chisholm Chisholm & Kilpatrick LTD (CCK Law), a preeminent veterans disability law firm, is excited to introduce a free, on-demand webinar aimed at assisting veterans in uncovering valuable VA benefits that many may be unaware of. Insights from the Experts The webinar, dubbed "Biggest Benefits Veterans Overlook,"...

Continue Reading
Tech Market Shifts: Navigating Opportunities and Challenges Ahead

Updated Category News Views 161

Understanding Recent Market Dynamics In recent weeks, global markets have been experiencing heightened volatility, particularly in the technology sector. With various significant events unfolding—including new political leadership in Japan and shifts in economic data—investors are carefully analyzing these developments to navigate potential risks and opportunities....

Continue Reading
Michael Beland Joins Advance Auto Parts as Chief Accounting Officer

Updated Category News Views 720

Welcome Michael Beland to Advance Auto Parts Advance Auto Parts, Inc. (NYSE: AAP), known for its significant role in the automotive aftermarket, recently made an important announcement regarding its executive leadership. The company has appointed Michael Beland as the new senior vice president, controller, and chief accounting officer, marking a pivotal addition to their...

Continue Reading
Recall Movement Against Governor Newsom Gains Momentum

Updated Category News Views 276

Recall Movement Gains Traction in California In an unprecedented move, SavingCalifornia.vote has taken a significant step to initiate a recall against Governor Gavin Newsom. This initiative marks a pivotal moment in California's political landscape. The organization is gathering support and will soon submit the official notice of intent to recall, alongside the necessary...

Continue Reading